Archives

by in
Entry Author Date Location
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
Verdezyne Gets $48M to Advance Industrial Biotechnology in Malaysia 04/29/14 San Diego
Novomer Obtains New Financing 12/10/13 Boston
Fate Therapeutics Joins Biotech IPO Conga Line, Reaching for $69M 08/14/13 San Diego
VLST, After Nine Years and $50M, Sells Assets and Winds Down 08/07/13 Seattle
NanoString Technologies Maneuvers In Line for $86M IPO 05/20/13 Seattle
Confirmed: Ignition Partners Scaling Down With New $150M Fund 01/24/13 Seattle
Seattle Smorgasbord: UW Molecule, Telanetix Sold, Symform CEO, and More 01/24/13 Seattle
New Finance Models For NW Cleantech, Sustainability As VC Wanes 01/08/13 Seattle
NanoString Pockets $15.3M For Diagnostic Rollout 12/04/12 Seattle
NanoString Technologies Garners $15,300,000 Series E Financing Round 12/03/12 Seattle
Exclusive: Skyline Ventures Cuts Partners, Postpones Fundraising 10/26/12 National
Which VCs Are Poised to Cash In On the Biotech IPOs of 2012? 10/15/12 National
VLST Cuts Scientific Group As Focus Shifts to Clinical Trials 09/27/12 Seattle
San Diego Life Sciences Roundup: Regulus IPO, Fate Funding, & More 08/23/12 San Diego
Adapx Secures $3,000,000 New Round 07/30/12 Seattle
NanoString Makes IPO Prep Move, Adds Finance Vet to Board 07/18/12 Seattle
Accelerator Looks to Expand, With an Eye on the Big Apple 06/01/12 Seattle
Verdezyne Raises $10.6M to Advance Sustainable Chemicals Technology 05/11/12 San Diego
Symform Receives $11,000,000 Series B Round 04/25/12 Seattle
Some Tongue-in-Cheek Fantasy Baseball (and Biotech) Picks 03/26/12 National
OVP, Looking for a Home Run, Hits Bunt Single With Complete Genomics 03/21/12 Seattle
DataSphere Obtains $8,000,000 Series D Financing Round 03/15/12 Seattle
Allozyne “Redistributes” Workforce After Scrapping Poniard Merger Plan 01/03/12 Seattle
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles 12/23/11 Seattle
Allozyne Receives New Round 12/23/11 Seattle
Allozyne, Poniard Scrap Plan to Merge Amid Investor Apathy 12/22/11 Seattle
Fate Therapeutics Names Biotech Vet Bill Rastetter as Chairman, Interim CEO 12/14/11 San Diego
Groove Biopharma Snags $6M to Push the Frontiers With MicroRNA Drugs 12/12/11 Seattle
Groove Biopharma Receives $8,000,000 Series B Financing 12/12/11 Seattle
Page 1 of 8 next page »